Timothy Wollaeger, M.B.A. Managing Director Emeritus

Timothy Wollaeger has more than forty years’ experience in the medical products and biotechnology fields in both corporate management and venture capital. Mr. Wollaeger joined Sanderling Ventures as a Managing Director in 2002, and opened the firm’s San Diego office. Mr. Wollaeger serves on the Board of Directors for several Sanderling portfolio companies, including CalciMedica and Chimerix (NASDAQ: CMRX). He is Chairman of the Board of Directors for Sotera Wireless and Asteres.

Prior to joining Sanderling in 1994, Mr. Wollaeger founded the venture capital firm Kingsbury Capital Partners. At Kingsbury, seed and early stage investing was combined with active management and portfolio companies included Aurora Biosciences, Amylin Pharmaceuticals, Senomyx (NASDAQ: SNMX), and Althea Technologies. Aurora was acquired by Vertex Pharmaceuticals (NASDAQ: VRTX) in 2001 for $600 million. Amylin was acquired by Bristol-Myers Squibb (NYSE: BMY) in 2012 for a total consideration of $7 billion. Althea was acquired by Japan’s Ajinomoto in 2013 for $175 million. He was named E&Y San Diego’s Entrepreneur of the Year in 1995, Corporate Director of the Year in 2001 and was awarded a Lifetime Achievement Award from the San Diego Corporate Directors Forum in 2013.

Prior to Kingsbury Capital Partners, Mr. Wollaeger helped found Columbia Hospital Corporation in 1990 and was a Senior Vice President and member of the Board of Directors until 1994. In 1986, Mr. Wollaeger became a founding General Partner of Biovest, a San Diego based venture capital firm. At Biovest, he helped found Pyxis, Biosite, Amylin Pharmaceuticals and Vical (NASDAQ: VICL). All four of these companies became public. Pyxis was acquired by Cardinal Health in 1996 for $1 billion (now CareFusion, NYSE: CFN), Biosite was acquired by Inverness Technologies Inc. in 2007 for $1.7 billion (now Alere, NYSE: ALR).

In 1983, Mr. Wollaeger joined Hybritech, Inc., San Diego’s first biotechnology company, as Vice President and Chief Financial Officer until Hybritech was acquired by Eli Lilly & Co. (NYSE: LLY) in 1986. He began his Life Science career at Baxter International where he was Manager of Operations Analysis. His last position was Vice President and General Manager of the Company’s operations in Mexico.

Mr. Wollaeger earned a B.A. in Economics from Yale in 1966, served as an officer in the U.S. Navy for three years, and earned an MBA from The Stanford Graduate School of Business in 1971.